Intravenous Ascorbic Acid (IVAA) for COVID-19 Supportive Treatment in Hospitalized COVID-19 Patients (Based on use in China and US settings)

Abstract:  Intravenous ascorbic acid (IVAA) is a well-known intervention in medicine, which currently is rarely used  in US hospitals. Due to the unusual and extreme clinical demands of hospitalized COVID-19 patients, IVAA has been implemented in Chinese hospitals, and data published by the “Expert Group on Clinical  Treatment of New Corona Virus Disease in Shanghai” (direct translation) details the use of IVAA as safe  and effective adjunctive care of hospitalized COVID-19 patients. In the IVAA treated group, there was no  mortality, no reported side effects, and shorter hospital stays universally. In addition, the Shanghai  Expert Group recommends IVAA use in extremely critical settings within COVID-19 patients. IVAA, as an  intervention, is relatively inexpensive and simple for both pharmacy and nursing staff use. The primary  author has also used IVAA in the US under a NIH funded human trial and has extensive subject matter  knowledge and expertise.